As posted in the ASCO Daily News, Dr. George Demetri, has received recognition for his work in developing targeted TKIs for GIST.
LRG’s Senior Director of Research, Pete Knox has summarized the ten key studies relating to GIST that are being presented at the American Society of Clinical Oncology's Annual meeting. ASCO20 is virtual this year.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Marlene Nei shares her story.
The Phase One Foundation has awarded GIST Specialist Jason Sicklick a $500,000 grant to study GIST in a Temozolomide Phase II clinical trial.
The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.
This discussion reviewed CRCI in general, and how a person who is being treated for GIST could be affected. We also talked about strategies that can help ameliorate CRCI, new research on CRCI and GIST. we also gave advice on how cancer survivors can best cope with and care for themselves during this unusual global health event.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
Although the ASCO (American Society for Clinical Oncology) will be a virtual meeting this year, The Life Raft Group continues to be at the forefront in collaborating in efforts to improve treatment for cancer patients. This year, two important abstracts will be presented online that illustrate these efforts.
This study is the result of a collaborative effort between Chile and Mexico, called Salud con Datos that sought to determine GIST prevalence, patients’ clinical characteristics and survival rates. Our report is the largest of its kind in Latin America.
The LRG has been granted permission from the NCCN to share the most recent NCCN Guidelines for Patients® with soft tissue sarcoma, most specifically the section on GIST, which the LRG has endorsed.